Osmotica Pharmaceutical Corp. Announces the Appointment of Darren Alkins as Executive Vice President

<0> Osmotica Pharmaceutical Corp.William H. Underwood, 910-509-0114Sr. Vice President, Business Development </0>

Osmotica Pharmaceutical Corp. today announced the appointment of Darren Alkins as Executive Vice President. Forrest Waldon, CEO of Osmotica Pharmaceutical stated, “We are pleased to announce that Darren Alkins has joined us as Executive Vice President. Darren brings a wealth of pharmaceutical industry experience to us and will help lead our growth and expansion efforts.”

“I am excited to join Osmotica at this important time in the company’s history. I look forward to working with the professionals at Osmotica to aggressively grow the company,” Mr. Alkins added.

Prior to joining Osmotica Pharmaceutical, Mr. Alkins served as Vice President of Business Development and Alliance Management at Teva Pharmaceuticals where he served on the US executive team. In his twenty-three year career in the pharmaceutical industry, Mr. Alkins has served as president of Glades Pharmaceuticals and in various senior positions at Bristol Myers Squibb.

Osmotica Pharmaceutical is a global specialty pharmaceutical company with a proven history of developing commercially successful pharmaceutical products. The company uses its proprietary osmotic technology platform and with strategic partners develops and commercializes high quality pharmaceutical products. In addition to the products currently on the market, the company’s pipeline includes several neurology-based therapeutic drugs.

Osmotica Pharmaceutical and its related companies form an international group of companies with principal operations located in the United States, Argentina and Hungary.

For more information on the Company, please visit Osmotica’s website at . This press release is directed to residents of the United States.

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

The 100 largest companies trading on the London Stock Exchange have boosted the percentage of women on their boards, but has life sciences kept pace?

In this week's EuroBiotech Report, Bicycle lands Genentech collaboration, GSK inks COVOD-19 adjuvant deal and Grifols buys antibiotic assets.